🟢 CSL is trading 17% up today after better-than-expected FY26 underlying earnings

CSL is trading at $28.03 (+17.04%) after better-than-expected FY26 underlying earnings and approximately 5% FY27 underlying profit growth guidance.

• Investors looked past the $2.6 billion statutory loss, largely caused by $7.1 billion in impairments and restructuring costs.
• CSL announced a $1.1 billion share buyback and maintained its $1.62 final dividend.
• The move is company-driven, with plasma recovery expectations outweighing near-term restructuring charges; healthcare was the strongest Australian sector on August 18, 2026.